Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...